ESTRO 2024 - Abstract Book

S421

Brachytherapy - Urology

ESTRO 2024

Patients were divided between low comorbidity (up to 3 drugs from these groups) and high comorbidity (more than 3 drugs). Association between BCF and OS were analyzed in each comorbidity group using Kaplan Meier model with SPSS v25.

Results:

A retrospective series of 801 patients treated in our department from 2008-2020 were included in the analysis. With a mean age of 69.8 years and a median follow up of 64 months, 481 patients (60.05%) were treated in the EBRT group and 320 (39.95%) in the HDR-BT group, with statistical differences in BCF and metastatic free survival previously reported, but no differences in OS. 208 patients (25.9%) were included in the low comorbidity group, and 593 (74.1%) in the high comorbidity group. We analyzed in each comorbidity group the association between BCF and OS in patients in the low comorbidity group (LogRank test p=0.007 ) with no statistical association in the high comorbidity group (LogRank test p=0.483). Image1 .

Image1.

Conclusion:

Association between BCF and OS in patients with low comorbidity supports recommendation of treatment options with biochemical failure benefit, such as brachytherapy boost , in high and very high risk patients.

Keywords: Comorbidity, PSA failure, Overall Survival.

References:

https://ascopubs.org/doi/full/10.1200/JCO.2016.68.4530